Medplus Halts CAPEX; Cipla Dips, PVR Inox Surges in Mixed Q1

The first quarter of June 2026 brought a mixed bag of corporate strategies and financial results, with **Medplus Health Services** halting its capital expenditure plans while several major companies reported varied earnings.

Medplus Rethinks Growth Strategy

Medplus Health Services confirmed it is putting previously approved CAPEX plans in abeyance. This strategic pause comes as the company reviews its current business structure and broader market outlook.

The halted plans include a **Food Park** project by its subsidiary Optival Health Solutions. Additionally, the company is pausing the development of a centralized fulfillment centre, reflecting a cautious approach.

Q1 Earnings Paint a Divergent Picture

The June 2026 quarter financial reports revealed significant performance disparities across key sectors, indicating a challenging but also opportunistic environment for some.

Pharmaceutical major **Cipla** saw its Profit After Tax (PAT) decline **33.84%**, reaching **Rs 8,621.60 million** compared to Rs 13,031.30 million year-over-year. Despite this, total revenue experienced a marginal 0.62% increase to **Rs 50,776.80 million**.

**Control Print** reported a substantial **41.73%** drop in Net Profit, settling at **Rs 123.90 million** from Rs 212.63 million in the same quarter last year. Its revenue, however, recorded a minor 4.16% increase, reaching **Rs 1,046.29 million**.

Retailer **Vishal Mega Mart** demonstrated strong top-line growth, with revenue zooming **13.06%** to **Rs 18,873.10 million**. Conversely, its Profit After Tax saw a slender 1.94% decline, falling to **Rs 1,731.90 million** from Rs 1,766.20 million.

In stark contrast, multiplex chain **PVR Inox** delivered a robust turnaround, moving from a substantial loss to profitability in the June 2026 quarter. The company reported a Profit After Tax of **Rs 516.00 million**, a significant recovery from a **Rs -512.00 million** loss in the prior year.

PVR Inox’s revenue climbed **15.27%** to **Rs 15,825.00 million**, accompanied by an increase in operating profit to **Rs 5,443.00 million** from Rs 4,270.00 million. This performance highlights a strong rebound for the entertainment giant.

Leadership Transitions at Sanofi India

Beyond earnings, corporate leadership saw a notable shift at **Sanofi India**, highlighting ongoing organizational adjustments within the pharmaceutical giant.

**Rachid Ayari**, serving as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel, announced his resignation. His departure is effective **September 30, 2026**, as he transitions to another role within the broader Sanofi group.

These diverse Q1 outcomes across healthcare, retail, and entertainment underscore the varied pressures and opportunities facing Indian businesses as they recalibrate strategies for the evolving market.